- Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Regeneron
- FDA Approves Libtayo for…
Category: 6. Business
-
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation – Regeneron
-
Silver’s Historic $50 Per Ounce Test Likely Imminent
Silver’s Historic $50 Per Ounce Test Likely Imminent | The Jerusalem PostJerusalem Post/Business & InnovationSilver’s rally is accelerating as global demand surges and supply tightens. Analysts say the metal’s long-awaited test of the…
Continue Reading
-
Fed minutes September 2025
Federal Reserve officials in September were strongly inclined to lower interest rates, with the only dispute seeming to be over how many cuts were coming, meeting minutes released Wednesday showed.
The meeting summary indicated near unanimity…
Continue Reading
-
Using generative AI to diversify virtual training grounds for robots | MIT News
Chatbots like ChatGPT and Claude have experienced a meteoric rise in usage over the past three years because they can help you with a wide range of tasks. Whether you’re writing Shakespearean sonnets, debugging code, or…
Continue Reading
-
Preparing Your Organisation for CSRD Through Strategic Scenario Planning
Organisations across Europe are navigating a pivotal moment. The accelerating pace of change, driven by political shifts, economic uncertainty, social transformation, rapid technological advances, and intensifying environmental pressures (
Continue Reading
-
FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma
The FDA has granted fast track designation to VT3989, a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, for the treatment of patients with unresectable malignant nonpleural or pleural mesothelioma who have…
Continue Reading
-
ADVISORY: Embargoed Press Call on the State of Climate Action 2025 Report
WASHINGTON (October 16, 2025) – Join an embargoed press call to preview the State of Climate Action 2025 report on Thursday, October 16, 2025, from 9:00–10:00 a.m. ET / 3:00–4:00 p.m. CEST, hosted by Systems Change Lab partners…
Continue Reading
-
Celebrating milestones and the future of oncology in China
China’s biopharmaceutical innovation is experiencing an unprecedented period of growth. Thanks to sustained policy support, capital investment, and expanding research capabilities, the country is rapidly increasing its reputation as a global…
Continue Reading
-
Kirkland Represents CF PharmTech on its Hong Kong Listing | News
Kirkland & Ellis advised CF PharmTech, Inc. (CF PharmTech, HKEx: 2652) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange. The joint sponsors for the listing were CITIC…
Continue Reading
-
Amazon announces plans to invest over €1 billion to enhance Belgian customer experience
During a Belgian Economic Mission to the West Coast of the USA, today we announced plans to invest over €1 billion in Belgium from 2025-2027. This investment continues Amazon’s commitment to innovation and providing an even better experience to…
Continue Reading